Biogen Inc (BIIB) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

Total Assets Chart for Biogen Inc

Biogen Inc (BIIB) total assets for FY2025 were USD 29.4B, a 5.0% change from FY2024. Biogen Inc's total assets grew from USD 85.8M in 1985 to USD 29.4B in 2025 (34211.8% over 40 years). Total assets compound annual growth rate: 5-year CAGR of 3.6%, 10-year CAGR of 4.2%, 20-year CAGR of 6.5%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$36.90B
Implied Share Price
$249.65
Enterprise Value
$42.57B
Revenue (TTM)
$10.30B
EBITDA
$2.79B
Profit Margin
3.38%
Trailing P/E
105.78
Forward P/E
14.97
Price/Book (MRQ)
1.91
Price/Sales (TTM)
3.58
EV/EBITDA
26.09
EV/Revenue
4.13
Dividend Yield
—
Book Value
$128.01
Free Cash Flow (FY2025)
$2.05B
Free Cash Flow Yield
5.56%

Snapshot as of 29th October 2026 — not point-in-time controlled, may lag the live market by a few days.